Navigation Links
Watson Completes Acquisition of Eden Biodesign
Date:1/28/2010

usiness. These factors include, among others, the difficulty of predicting the regulatory pathway, if any, to obtain FDA approval of generic or "biosimilar" biologic products; risks that competitors will seek to prevent Watson from obtaining FDA or other regulatory agency approval of biologic products through legislative, regulatory or other means; risks that the carrying values of assets may be negatively impacted by future events and circumstances; timely and successful consummation and implementation of strategic initiatives; the timing and success of product launches; the difficulty of predicting the timing or outcome of product development efforts and FDA or other regulatory agency approvals or actions; the uncertainty associated with the identification and successful consummation of external business development transactions; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson's and its third party manufacturers' facilities, products and/or businesses; periodic dependence on a small number of products for a material source of net revenue or income; changes in generally accepted accounting principles; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report on Form 10-K for the period ended December 31, 2008 and quarterly report on Form 10-Q for the period ended September 30, 2009. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
2. Watson Files FDA Application for Generic Rozerem(R)
3. Watson to Present at Credit Suisse Healthcare Conference
4. Watson and Barr Settle Lawsuit Over Oxytrol(R)
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
7. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
8. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
9. Watson Launches Generic Biaxin(R) XL
10. World Heart Corp. Completes $7.3 Million Private Placement
11. Ethicon Completes Acquisition of Acclarent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Research and Markets ( ... "Investigation Report on China,s Insulin Aspart Market, ... Developed by Novo Nordisk, insulin aspart (under the ... for the treatment of diabetes. Compared with human ... analog, starts working fast and reports higher peak ...
(Date:8/28/2015)... , August 28, 2015 The ... in collaboration with one of the leading academics in the ... (current world record holder in life extension for model animals ... into biology of aging and age-related diseases, primarily, around the ... work has just been published as "Stability analysis of a ...
(Date:8/28/2015)... -- Perrigo Company plc ("Perrigo") (NYSE: PRGO ; TASE) ... leading OTC brands from GSK in an all cash ... clear demonstration of Perrigo,s unique ability to maximize brand ... 36 countries.  Perrigo Chairman, President and ... excited to complete this transaction, which clearly demonstrates our ...
Breaking Medicine Technology:China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2Gero: Physics Meets Biology to Help Defeat Aging 2Gero: Physics Meets Biology to Help Defeat Aging 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4
... NEW YORK, March 7, 2011 Reportlinker.com ... is available in its catalogue: ... Future Growth to be Driven by Improving ... http://www.reportlinker.com/p0409144/Aesthetic-Devices-Market-to-2017---Future-Growth-to-be-Driven-by-Improving-Treatment-Outcomes-and-Increase-in-Consumer-Confidence.html ...
... Therapeutics Inc. (TSX: NPC), today announced that their March ... LINK: www.retailinvestorconferences.com Click the red "register/ ... will be available 24/7 for 90 days. Investors may ... the next three weeks. About Allon ...
Cached Medicine Technology:Reportlinker Adds Aesthetic Devices Market to 2017 - Future Growth to be Driven by Improving Treatment Outcomes and Increase in Consumer Confidence 2Reportlinker Adds Aesthetic Devices Market to 2017 - Future Growth to be Driven by Improving Treatment Outcomes and Increase in Consumer Confidence 3Allon Therapeutics' CEO Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com 2Allon Therapeutics' CEO Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com 3
(Date:8/28/2015)... ... August 28, 2015 , ... The Nashville Business Journal recently ... in business. Mr. Troy Mizell, Chairman of the Board at MyGenetx, is ... 2015 Veterans Awards will recognize Nashville military veterans who, through their professional and ...
(Date:8/28/2015)... ... August 28, 2015 , ... SmartPractice Calendars afford ... with practice contact information and logos, Calendars stand alone as functional brand-building ... into seasonal mailings, thank you and welcome communications, and to complement statements and ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... Mendon, IL, ... of good music and good people, all for a good cause. In its second ... 2015, sponsored once more by Best Drug Rehabilitation. The “Mission” of “Music With A ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Louis W. ... technology innovation to transform quality and efficiency of healthcare delivery worldwide, announced the ... and aggregated before being publicly shared to document progress and inform policy in ...
(Date:8/28/2015)... ... August 28, 2015 , ... United Benefit Advisors ... TJS Insurance Group as its newest Partner Firm. Founded in 1924 and headquartered ... them focused on their goals. Within the past 10 years, TJS Insurance Group ...
Breaking Medicine News(10 mins):Health News:MyGenetx Board Member Receives Veterans Award 2Health News:SmartPractice® Introduces 2016 Calendars for Dental Practice Giveaways 2Health News:Best Drug Rehabilitation Sponsors "Music With A Mission" Concert Featuring Avenue Beat 2Health News:WEDI's The Sullivan Institute for Healthcare Innovation Releases Gaps in Care Survey 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 3
... , HORSHAM, Pa., Dec. 7 Teva Respiratory, ... ), today announced the publication of four articles in a ... of Allergy and Clinical Immunology (JACI), providing a comprehensive ... in the understanding and treatment of asthma. This represents the ...
... and treatment explain decrease , MONDAY, Dec. 7 (HealthDay ... have all continued to help cut the annual number ... a new report says. , The findings showed that ... significantly for both men and women and for most ...
... genetic approach to treating sickle cell disease is showing promising ... inactivating a gene they previously discovered to be important in ... healthy fetal form of hemoglobin in the mice, potentially compensating ... to "sickle" and obstruct blood flow. The study was ...
... ... ... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has begun shipping ... of Tamiflu will begin arriving in pharmacies nationwide and will continue to roll out to ...
... patients on Paxil became more extraverted and less ... (HealthDay News) -- Taking antidepressants may not only ... extraverted and less neurotic, new research suggests. , ... believed to help protect from depression, while neuroticism, ...
... ... today, Dr. David Hunt, a range of experts and healthcare leaders will focus on ... New Zealand healthcare industries will discuss lessons learned in developing functional health information exchanges ... ...
Cached Medicine News:Health News:Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 2Health News:Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 3Health News:Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 4Health News:Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 5Health News:U.S. Cancer Cases, Deaths Continue to Drop 2Health News:U.S. Cancer Cases, Deaths Continue to Drop 3Health News:U.S. Cancer Cases, Deaths Continue to Drop 4Health News:New approach to sickle-cell disease shows promise in mice 2Health News:Roche Announces Shipments of New Supplies of Children's Tamiflu in the U.S. 2Health News:Roche Announces Shipments of New Supplies of Children's Tamiflu in the U.S. 3Health News:Roche Announces Shipments of New Supplies of Children's Tamiflu in the U.S. 4Health News:Roche Announces Shipments of New Supplies of Children's Tamiflu in the U.S. 5Health News:Antidepressants May Change Your Personality 2Health News:Antidepressants May Change Your Personality 3Health News:Antidepressants May Change Your Personality 4Health News:Orion Health Participates in International Forum to Break Down Barriers for Health Information Exchange 2Health News:Orion Health Participates in International Forum to Break Down Barriers for Health Information Exchange 3
Used for vascular access. Supplied sterile in peel-open packages. Intended for one-time use....
Used for arterial and venous punctures. The tapered hub design of the catheter facilitates wire guide introduction. Supplied sterile in peel-open packages. Intended for one-time use....
Used for placement of .035 inch (0.89 mm) or .038 inch (0.97 mm) diameter wire guides into the vascular system when a small 21 gage needle stick is desired....
Used to introduce balloon, closed and non-tapered end catheters or other devices for intervention....
Medicine Products: